NIAID - VRC - Pre-Clinical Assessment of monoclonal antibodies and other promising vaccines/agents

NIAID - VRC - 单克隆抗体和其他有前途的疫苗/制剂的临床前评估

• 批准号: 10722428
• 负责人: CHRISTOPHER CASE
• 金额: $ 219.83万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2027-09-11
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10722428
• 关键词: Antibodies; Communicable Diseases; Data; Disease; Disease Outbreaks; Ebola; Emerging Communicable Diseases; Evaluation; Future; HIV; Health; Human; Investigational New Drug Application; Malaria; Mission; Monoclonal Antibodies; National Institute of Allergy and Infectious Disease; Public Health; Vaccines; ZIKA; human disease; improved; pandemic influenza; pathogen; pre-clinical assessment; preclinical safety; research and development; research clinical testing; therapeutic evaluation

The VRC is dedicated to improving global human health through the rigorous pursuit of effective vaccines for human diseases. The NIAID mission and scope includes rapidly responding to infectious disease outbreaks through research, development and clinical testing of therapeutics and vaccines against diseases caused by pathogens that threaten public health such as, HIV, pandemic influenza, and emerging and re-emerging infectious diseases like Ebola, Zika, and Malaria.

VRC致力于通过严格追求人类疾病的有效疫苗来改善全球人类健康。 NIAID的任务和范围包括通过研究，开发和临床检测对感染性疾病暴发的迅速反应，该疗法和疫苗针对因病原体而引起的疾病，威胁着艾滋病毒，艾滋病毒，大流行性流感，以及出现的伊博拉病毒，例如艾滋病毒，艾滋病毒，疾病。 ，寨卡和疟疾。